A Phase 1 SARS-CoV-2 Vaccine Study to Assess the Safety and Tolerability of GRT-R912 or GRT-R914 Administered as Prime and/or Boost in Healthy Adult Volunteers Naïve to SARS-CoV-2, SARS-CoV-2 Convalescent Subjects, and People Living with HIV.


This Phase 1 clinical trial will assess the potential of Gritstone’s second-generation COVID-19 vaccines to generate B-cell and T-cell responses against SARS-CoV-2 in both PLWH and HIV negative subjects, in subjects who have previously been infected by SARS-CoV-2, and those who have neither been infected with nor vaccinated against SARS-CoV-2. GRT-R912 and GRTR914 are vaccines using a SAM vector based on proteins from the Venezuelan Equine Encephalitis (VEE) virus in a homologous prime-boost regimen, providing an option for a potent, single-modality approach. Gritstone has optimized the vector cassettes tailored to SARSCoV-2, specifically the beta variant, and designed them to induce balanced T-cell and antibody responses.


  • Dr Mrinmayee Dhar, Principal Investigator
  • Dr Faeezah Patel
  • Dr Elizea Horne
  • Dr Muneerah Khan
  • Dr Jeanne Coetzee
  • Prof Lee Fairlie
  • Tiffany Seef
  • Othusitse Segalo

Latest Update

December 2023

For more about GO-012 please email

Research and Policy Briefs


Stay up to date

Get updates on news, resources, events and happenings from Wits RHI.